First prospective clinical feasibility study suggests nsPFA may be a safe and effective method for treating benign thyroid tumors or nodules
HAYWARD, Calif.--(BUSINESS WIRE)--Sep. 27, 2023--
Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in two poster presentations at the upcoming American Thyroid Association 2023 Annual Meeting in Washington D.C. from September 27th to October 1st, 2023.
“I am proud to have been a part of the first human surgical procedure study on benign thyroid nodules conducted with the nsPFA technology. In the treated regions, we observed complete ablation of the cellular tissue without evidence of thermal necrosis or damage to noncellular structures, as is typically the case with current thermal treatment modalities,” said Dr. Stefano Spiezia, Chief of Endocrine Surgery Division at Napoli Ospedale del Mare and principal investigator of the study. “We look forward to sharing these promising results with our esteemed colleagues at the ATA meeting and continuing our work with nsPFA.”
“The findings from this study are extremely compelling and suggest that nsPFA could represent a significant advancement in the treatment of symptomatic benign thyroid nodules,” said Dr. Ralph Tufano, Director of Head and Neck Endocrine Surgery at Sarasota Memorial Health Care System. “The exciting possibility of a new energy modality with improved speed and safety around critical structures, such as nerves and blood vessels, could be a game-changer for many of these patients."
Late Breaking Abstract Poster Presentations
First Prospective Clinical Feasibility Study Using Nanosecond Pulsed Field Ablation (nsPFA) for the Treatment of Benign Thyroid Nodules – Histological Assessment
S. Spiezia, C. Offi, C. Misso, G. Antonelli, A. D’Antonio, R. P. Tufano and W. A. Knape
Advantages of nsPFA technology includes cellular tissue selectivity, sharp ablation zone margins, absence of thermally induced necrosis, and short treatment times. This feasibility study suggests nsPFA may be a safe and effective method for treating benign thyroid tumors or nodules.
First Prospective Clinical Feasibility Study Using Nanosecond Pulsed Field Ablation (nsPFA) for the Treatment of Benign Thyroid Nodules – Ultrasound Assessment
S. Spiezia, C. Offi, C. Misso, G. Antonelli, A. D’Antonio, R. P. Tufano and W. Knape
This feasibility study suggests nsPFA may be a safe and effective method for treating benign thyroid tumors or nodules.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where nsPFA could have a profound positive impact on healthcare for both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230927931125/en/
Kevin Danahy, President and CEO
Philip Trip Taylor
Source: Pulse Biosciences, Inc.